💊
Capvaxive
pneumococcal polysaccharide conjugate vaccine (21-valent)
Infecciones neumocócicas
✅ Autorizado
✅
No hay alertas activas
Este medicamento no tiene escasez en curso, cartas de seguridad ni retiradas del mercado.
Para qué se utiliza
Capvaxive is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.The use of Capvaxive should be in accordance with official recommendations.
⚠️ Seguridad del paciente
No
Página oficial de la EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/capvaxive